Johnson & Johnson said it would purchase privately held drug developer Alios BioPharma Inc for $1.75 billion in cash, to access a portfolio of drugs targeting viral infections. Johnson & Johnson said the deal includes Alios's experimental drug for infants with respiratory syncytial virus.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Shares of JNJ remained unchanged at $106.54. In the past year, the shares have traded as low as $85.50 and as high as $108.77. On average, 6244570 shares of JNJ exchange hands on a given day and today's volume is recorded at 0.
Source
